Avery Smith
Gastroenterology · Abilene, TXNPI 1578983771
Payments from drug & device makers
Across 262 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$563
- Pfizer$327
- Celltrion USA Inc.$306
- Regeneron Healthcare Solutions, Inc.$294
- Johnson & Johnson$179
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,27397%
- Education$1183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $1,262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $563 |
| Pfizer | 17 | $327 |
| Celltrion USA Inc. | 17 | $306 |
| Regeneron Healthcare Solutions, Inc. | 16 | $294 |
| Johnson & Johnson | 9 | $179 |
| Boston Scientific | 4 | $162 |
| Aimmune Therapeutics, Inc. | 9 | $157 |
| QOL Medical, LLC | 7 | $114 |
| AstraZeneca | 5 | $110 |
| Merck | 8 | $108 |
| Phathom Pharmaceuticals, Inc. | 12 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $88 |
| Redhill Biopharma Inc. | 4 | $79 |
| Intercept Pharmaceuticals, Inc. | 5 | $78 |
| Covidien LP | 1 | $65 |
| Ardelyx, Inc. | 2 | $48 |
| Gilead | 3 | $41 |
| Braintree Laboratories, Inc. | 3 | $38 |
| Madrigal Pharmaceuticals | 2 | $36 |
| Bristol Myers Squibb | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Echosens North America, Inc. | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Aries Pharmaceuticals, Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Endo USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HYDRATOME$109
How this compares
$4,391 in reported general payments places this provider in the 50th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 12 | $79,297 |
| XifaxanRifaximin | 17 | $68,159 |
| LinzessLinaclotide | 83 | $49,921 |
| VoqueznaVonoprazan Fumarate | 20 | $13,725 |
| TrulancePlecanatide | 14 | $11,796 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 63 | $10,116 |
| Sucralfate | 103 | $6,297 |
| Colestipol Hcl | 96 | $5,126 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 42 | $5,065 |
| Pantoprazole Sodium | 672 | $4,833 |
| Mesalamine | 22 | $4,529 |
| Famotidine | 497 | $4,153 |
| Budesonide DrBudesonide | 41 | $3,025 |
| Ursodiol | 44 | $2,376 |
| Dicyclomine Hcl | 152 | $2,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $88 | $79,95531 claims |
| AbbVieLinzess | $1,262 | $49,92183 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $38 | $15,181105 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $103 | $13,72520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Abilene
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Stephen HarrisonLive Oak$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.